Dr. Guangyao Li is a Research Fellow in the Department of Applied Mathematics and Theoretical Physics (DAMTP) at the University of Cambridge, affiliated with the Quantum Fluids research group. His work focuses on theoretical and computational studies of quantum fluids, particularly exciton-polaritons in semiconductor microcavities and their interactions with electrons and photons. His research bridges condensed matter physics, quantum optics, and nanotechnology. Dr. Li's interdisciplinary interests also extend to pharmacology and clinical medicine, evidenced by collaborative studies on drug efficacy, drug-related problems in hospital settings, and guidelines for off-label drug use in ophthalmology. These studies address topics such as glucocorticoid therapy complications, proton pump inhibitor utilization, and anti-vascular endothelial growth factor treatments for ocular diseases. His quantum physics publications explore polariton scattering, Bose-Einstein condensates, and chiral edge states in quantum fluids. Recent medical studies analyze drug safety, self-monitoring in diabetes, and inappropriate medication use in elderly cardiac patients. These works highlight his dual contribution to fundamental physics research and applied clinical pharmacology. No academic awards or grants are explicitly stated in available records. He advises no known students but collaborates across disciplines in Cambridge and Chinese medical institutions. His research is conducted within the Quantum Fluids group at DAMTP, leveraging advanced theoretical models and computational simulations.
Dr. Anagha Vaze is a Clinical Lecturer affiliated with the University of Sydney's Faculty of Medicine and Health (FMH) and the Save Sight Institute. Her expertise lies in ophthalmology, with a focus on retinal disorders, diabetic eye diseases, and clinical research. She has contributed to studies on VEGF inhibitors, corticosteroid delivery platforms for macular edema, and the application of genomics in retinal diagnostics. Research Interests: Retinal degeneration and vascular abnormalities Management strategies for diabetic retinopathy and macular telangiectasia Clinical outcomes of anti-VEGF therapies Infectious diseases in immunocompromised patients (e.g., heart transplant recipients) Her publications (2014–2022) emphasize observational studies, drug delivery innovations, and case reports on rare infections. Key contributions include assessing treatment discontinuation protocols for neovascular AMD and exploring photobiomodulation for diabetic macular edema. While no scientific awards or grants are explicitly listed, her work reflects active engagement in clinical research and patient care. She is part of the Save Sight Institute, a prominent research center within the FMH, focusing on vision science and ophthalmic advancements.
Prof. Dr. Kathrin Schumann is an Assistant Professor at the Technical University of Munich (TUM), leading the 'Engineering Immune Cells for Therapy' group within the TUM School of Medicine and Health. Her research focuses on CRISPR-based engineering of human immune cells to develop novel therapies for autoimmune and tumor diseases. She holds a doctorate from the Max Planck Institute of Biochemistry and has conducted postdoctoral research at the University of California, San Francisco, under Professors Alex Marson and Jeffrey Bluestone. Dr. Schumann’s academic career includes a Presidential Postdoc Fellowship at Novartis (Basel) and a tenure-track appointment at TUM since 2018. Her work emphasizes genomic editing of T cells to study gene function and improve cell therapy safety. Key research themes include CRISPR-mediated gene silencing, T cell receptor engineering, and HIV-host interaction studies. Education: Bachelor/Master in Biochemistry, University of Tübingen PhD, Max Planck Institute of Biochemistry (Martinsried) Postdoc, University of California, San Francisco (UCSF) Her research has yielded breakthroughs in CRISPR applications for T cell therapy, including PD-1 disruption to enhance anti-tumor efficacy and targeted editing of T cell receptors. Awards include a DFG research grant (2016). Notable achievements include the development of CRISPR ribonucleoprotein platforms for primary T cells and insights into metabolic checkpoints in T cell exhaustion. Her lab collaborates globally to translate CRISPR-based discoveries into clinical therapies.
Eric W. Schmidt is a Distinguished Professor of Medicinal Chemistry at the University of Utah, with adjunct appointments in Biological Sciences and Chemistry. His research focuses on natural products chemistry, biosynthesis, synthetic biology, and pharmaceutical applications of marine animal microbiomes. University of California, San Diego (BS, PhD) Research areas include: Biosynthesis in animals and their microbiomes Synthetic biology approaches to chemical engineering Drug design from marine natural products Metagenomic analysis of symbiotic relationships Neuroactive compound discovery Antibiotic development against resistant pathogens His lab has pioneered methods for: Biosynthetic gene cluster identification Heterologous expression in E. coli Enzymatic modification of peptides Chemical analysis of marine invertebrates Recent publications highlight discoveries in: Marine animal chemical defense mechanisms Evolution of biosynthetic pathways Antibiotic resistance profiling Ionic channel-targeting compounds Peptide macrocyclization techniques Lipid-polyketide biosynthesis continuum Email: ews1@utah.edu Honors include: Distinguished Professor recognition
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
Dr. Arpan Mehta is an Independent Investigator at the MRC Protein Phosphorylation and Ubiquitylation Unit, specializing in neurodegenerative diseases with a focus on Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia. He was awarded the 51st Sir John Halliday Croom Medal and Lectureship by the Royal College of Physicians of Edinburgh for his groundbreaking research on ALS mechanisms. His work explores the role of kinases and genetic mutations (e.g., C9ORF72) in neurodegeneration, alongside mitochondrial dysfunction and clinical trial methodologies. Research interests include molecular mechanisms underlying ALS, neuroimmunology, and improving clinical trial designs for neurodegenerative diseases. Dr. Mehta advocates for rigorous research standards, addressing reproducibility challenges, and optimizing therapeutic approaches. His recent studies investigate mitochondrial bioenergetic deficits in ALS motor neurons and the impact of cerebrospinal fluid (CSF) toxicity. Awards: Sir John Halliday Croom Medal and Lectureship (2025) His publications span clinical neurology, neurodegenerative disease mechanisms, and ethical aspects of medical practice. Dr. Mehta emphasizes interdisciplinary collaboration to advance understanding of ALS pathogenesis and translational therapies.
Antti Poso is a Professor of Drug Design at the University of Eastern Finland (Kuopio), affiliated with the School of Pharmacy under the Faculty of Health Sciences. His research focuses on computer-aided molecular design, particularly targeting anti-cancer drugs and anti-microbials. Key projects include the EDCMET project (2019–2024) and the GeneCellNano Flagship (2020–2028). He leads the Molecular Modeling and Drug Design Research Group, specializing in QSAR analysis, kinase inhibition profiling, and systems-level drug response modeling. Recent work includes studies on SARS-CoV-2 inhibitors, endocrine disruptors, and bacterial pathogenesis. His findings bridge chemical structure with biological outcomes, leveraging computational tools like CCA and molecular dynamics simulations. Collaborations span medicinal chemistry, pharmacology, and systems biology, contributing to both academic and applied drug discovery efforts. Education: Not explicitly stated in texts; assumed to hold advanced degrees in pharmacy or chemistry. Research Themes: Drug design, molecular modeling, QSAR, computational biology, and anti-infective agents. Key Contributions: Over 150+ publications, including influential works on chemoinformatics-driven drug response analysis and structure-based inhibitor design. Publications highlight advancements in kinase inhibitors, anti-microbial strategies, and viral hijacking mechanisms. His work emphasizes translating computational insights into therapeutic solutions for cancer, infectious diseases, and metabolic disorders.
Trond Vidar Hansen is a Professor at the Department of Pharmacy, University of Oslo , and leads the LIPCHEM research group . He collaborates with institutions including the University of Bergen and Vestlandets Innovasjonsselskap through the VITADEL project, which recently received NOK 5,000,000 in verification support from the Research Council of Norway. His research focuses on the synthesis and biological evaluation of specialized pro-resolving lipid mediators derived from omega-3 fatty acids, with applications in inflammation resolution, neuroinflammation, and drug development. University : University of Oslo Department : Department of Pharmacy Research Group : LIPCHEM Collaborations : University of Bergen, Vestlandets Innovasjonsselskap Research Interests : H Hansen's work centers on the organic synthesis of bioactive lipid derivatives, particularly pro-resolving mediators from omega-3 polyunsaturated fatty acids. His team investigates their roles in inflammatory disease models , neuroinflammation , and PPAR receptor activation , aiming to develop therapeutic agents for conditions like chronic pain, diabetes, and neurodegenerative disorders. The research integrates stereoselective chemistry , biochemical profiling , and pharmacological evaluation to validate these mediators' clinical potential. Recent Awards : 2025: NOK 2,000,000 verification support from Research Council of Norway 2025: Co-leader of NOK 5,000,000 VITADEL project Publications : His articles (2015–2024) reveal a focus on stereoselective synthesis of resolvins, protectins, and maresins, with applications in anti-inflammatory and neuroprotective therapies . Key subfields include omega-3 metabolite profiling , PPAR agonist design , and biosynthetic pathway elucidation , often utilizing human cell models and mouse disease models . Collaborative projects emphasize commercialization of academic research and translational medicine .
Hans Steenackers is an Associate Professor at the Faculty of Bioscience Engineering, KU Leuven, where he leads the MICA Lab within the Department of Microbial and Molecular Systems. His research focuses on innovative antimicrobial strategies targeting microbial communities, including socio-active, anti-resistance, and observation-guided approaches. Key research areas include biofilm dynamics antimicrobial resistance evolution in situ microbial monitoring Salmonella Typhimurium pathogenesis anti-virulence therapies His recent publications highlight advancements in biofilm inhibition, triggered antimicrobial release systems, and evolutionary robustness of probiotics. The majority of his work involves interdisciplinary collaborations, particularly in projects like TARDIS, ULTiMatE-MS, and MICROTUNe, with a focus on translating fundamental research into clinical applications. As an educator, he teaches advanced courses in microbial physiology, biofilm research, and applied biotechnology. The MICA Lab actively partners with academic and industrial stakeholders in initiatives such as the Flemish Scientific Research Network on Biofilms and the Bioclean H2020 project.
Moira Whyte serves as Sir John Crofton Professor of Respiratory Medicine and Head of Edinburgh Medical School at the University of Edinburgh, while directing the MRC University of Edinburgh Centre for Inflammation Research. Her leadership spans clinical academia and major research initiatives focused on respiratory pathophysiology. Her educational background includes a 1st Class B.Sc. (1981), M.B., B.S. (1984), and Ph.D. (1993) from the University of London, complemented by professional qualifications: M.R.C.P. (1987), F.R.C.P. (1998), and F.Med.Sci. (2005) from the Academy of Medical Sciences. Whyte's research centers on neutrophil biology, macrophage function, and hypoxia signaling pathways in respiratory diseases. Her work explores how oxygen-sensing mechanisms like HIF pathways regulate immune cell function in COPD, pulmonary fibrosis, and bacterial infections, with particular focus on cellular metabolism and inflammation resolution. Analysis of her 15 most recent publications reveals consistent focus on neutrophil and macrophage biology within respiratory diseases, with growing emphasis on metabolic regulation of immune responses. Her work bridges basic science (using zebrafish models) with clinical applications, particularly in COPD and pulmonary fibrosis. Her scientific recognition includes: 2014 OBE for Services to Respiratory Medicine 2014 Foundation Fellow of the European Respiratory Society 2005 Fellow, Academy of Medical Sciences 2002 Tudor Edwards Lecturer of the Royal College of Physicians 1994 Wellcome Trust Advanced Fellowship 1989 MRC Clinical Training Fellowship Whyte directs substantial research funding, including a £6.4M Wellcome Trust Clinical PhD Programme (ECAT-Plus) and multiple grants investigating macrophage function in COPD, hypoxia pathways in pulmonary fibrosis, and neutrophilic inflammation regulation. Her collaborative approach is evident in multi-institutional projects like the EME-TIPAC study on pulmonary fibrosis. As Director of the MRC Centre for Inflammation Research, she leads a multidisciplinary team investigating fundamental mechanisms of inflammation across multiple disease contexts, with particular strength in respiratory immunology and translational applications.
Prof. Dr. Nina Khanna Gremmelmaier leads the Infection Biology research group at the Department of Biomedicine, University of Basel , focusing on host-pathogen interactions in Staphylococcus aureus implant-associated infections and virus-specific T-cell therapies for transplant recipients. Her lab collaborates with the Department of Biosystems Science and Engineering (D-BSSE, ETH Zürich) to develop synthetic genetic circuits expressing lysostaphin for biofilm infection treatment, demonstrating superior efficacy over antibiotics in mouse models. Department of Biomedicine, University of Basel NCCR AntiResist grant recipient (2019) for interdisciplinary antibiotic resistance research Research priorities include: Translational strategies for biofilm-associated infections CD14/TLR-engineered cell-based anti-infective approaches Clinical T-cell therapy trials (NCTO2007356) for post-transplant viral infections Scientific contributions: NCCR AntiResist grant (2019) - University of Basel Contact: nina.khanna@unibas.ch
Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.
Thomas Efferth is Full Professor and Director of the Institute of Pharmaceutical and Biomedical Sciences at Johannes Gutenberg University Mainz, Germany. He leads the Department of Pharmaceutical Biology, specializing in molecular pharmacology and drug discovery. His research spans cancer therapeutics, infectious diseases, and traditional Chinese medicine, with a strong focus on artemisinin and natural products. Education includes a PhD from the German Cancer Research Center (1990) and habilitation from RWTH Aachen University (1997). Professional positions include research leadership at the German Cancer Research Center (2005), associate professorship at Heidelberg University (2007), and his current role since 2009. Research interests integrate systems biology approaches with: Molecular mechanisms of anticancer drugs Bioinformatic pharmacology for personalized medicine Artemisinin repurposing for cancer/viral infections Toxicological profiling of natural products Publications demonstrate strong focus on phytomedicine, antiviral therapies, and cancer drug resistance. Awards and honors include: Qihuang International Award (2017) World Academy of Sciences membership (2018) Stanford Top 2% Scientist citation ranking (2020) Dr. Wilmar Schwabe Award (2006) Multiple honorary professorships in China/Hong Kong Editorial leadership includes Editor-in-Chief roles for Phytomedicine and board memberships in 20+ journals. Society roles feature vice-presidency of the Specialty Committee on Immunology of TCM and executive positions in IUPHAR and DPhG.
Shabaz Mohammed is an Associate Professor of Proteomics at the University of Oxford, holding joint appointments in the Departments of Chemistry and Biochemistry. Since 2020, he has served as Head of the Mechanistic Proteomics research programme at the Rosalind Franklin Institute. His research focuses on advancing proteomics technologies to study protein post-translational modifications and their roles in cellular processes, with applications in viral infections and disease mechanisms. Education: BSc in Chemistry, UMIST (now The University of Manchester), 1999 PhD in Biological Mass Spectrometry, University of Manchester, 2003 Postdoctoral Research, University of Southern Denmark (with Ole Jensen), 2005-2008 Postdoctoral Research, Utrecht University (with Albert Heck), 2008 Professor Mohammed's research centers on developing novel mass spectrometry approaches for large-scale characterization of protein post-translational modifications (PTMs). His group innovates in chromatographic techniques for single-cell proteomics, creates materials for PTM enrichment (glycosylation/phosphorylation), and applies these tools to study viral infections (SARS-CoV-2), cell cycle regulation, and signaling pathways. His work bridges chemistry, biochemistry, and cell biology to understand dynamic protein functions in health and disease. His recent publications (2023-2025) demonstrate strong emphasis on viral proteomics, particularly virus-host RNA-binding protein interactions, and innovations in mass spectrometry fragmentation techniques and chromatography. Key themes include viral remodeling of host cells, new labeling strategies for PTMs, and advancements in single-cell proteomics, with significant implications for understanding viral pathogenesis. Scientific Awards: No specific awards or fellowships were detailed in the source material. Advising and Grants: Information regarding graduate students supervised or specific research grants was not provided in the available text. As an active research group leader, Professor Mohammed likely mentors PhD students and secures competitive funding for proteomics research. Laboratories and Collaborations: Professor Mohammed leads a research group at Oxford focused on proteomics technology development. He collaborates extensively with the Ben Davis group on PTM detection materials and across the university on biochemical applications. At the Rosalind Franklin Institute, he heads the Mechanistic Proteomics programme to unravel protein functions through advanced proteomic methods.
Sergio Infante, MD, is an Associate Professor in the Department of Medicine at the School of Medicine and an Assistant Professor in the Department of Pharmacy Practice at the School of Pharmacy, both at Loma Linda University. His dual appointment reflects his interdisciplinary expertise in clinical nephrology and pharmacy practice, particularly in managing patients with kidney disease and optimizing medication regimens in renal impairment. Associate Professor, Department of Medicine, School of Medicine, Loma Linda University Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, Loma Linda University Dr. Infante's research focuses on nephrology, transplantation, and pharmaceutical care in chronic and critical illness. His work addresses key clinical challenges such as drug dosing in continuous renal replacement therapy, bone health in dialysis patients, outcomes in kidney transplant recipients, and mental health in end-stage renal disease. He also investigates interdisciplinary models of care to improve patient adherence and outcomes in dialysis. His recent publications (2017–2024) demonstrate consistent scholarly output across nephrology, pharmacy, and internal medicine journals. These studies include case reports, clinical research, and interdisciplinary reviews, with a strong emphasis on practical applications in patient management. Themes in his research include mineral and bone disorders in CKD, ultrafiltration strategies, post-transplant complications, and the intersection of mental health with chronic kidney disease. Dr. Infante has been actively involved in multiple research projects, including investigator roles in industry-sponsored and internally funded studies. Notably, he served as Principal Investigator (PD/PI) on a grant from LLU-GRASP (2021–2025) examining lithium use in depression and suicidal ideation among ESRD patients, indicating leadership in psychonephrology research. Evaluation of polymyxin B hemoperfusion in septic shock (EUPHRATES) – Investigator (Spectral Diagnostics Inc., 2014–2015) Assessment of kidney disease in COVID-19 patients – Investigator (LLU Dept. of Medicine, 2021) Literacy and numeracy in dialysis medication labeling – Investigator (LLU Dept. of Pharmacy, 2019) Clinical outcomes of induction therapies in transplant patients – Investigator (LLU Transplantation Institute, 2007–2015) Role of lithium in depression in ESRD – PD/PI (LLU-GRASP, 2021–2025) While no formal lab or team is explicitly mentioned, his collaborative publications and project leadership suggest active participation in multidisciplinary research teams involving nephrology, pharmacy, psychiatry, and transplantation. His future work appears to focus on mental health in renal populations, patient education, and precision dosing in critical care nephrology.
